Guidelines for ATC classification and DDD assignment - WHOCC

M05BX Other drugs affecting bone structure and mineralization
202
The DDD for denosumab is based on the treatment of osteoporosis.
M09 OTHER DRUGS FOR DISORDERS OF THE MUSCULO-
SKELETAL SYSTEM
M09A OTHER DRUGS FOR DISORDERS OF THE MUSCULO-
SKELETAL SYSTEM
This group comprises preparations used in disorders of the musculoskeletal
system, which cannot be classified in the preceding groups.
M09AA Quinine and derivatives
M09AB Enzymes
Hydroquinine, which is used in the treatment of nocturnal leg cramps is
classified in this group.
Quinine is classified as an antimalaria agent in P01BC. Quinine in
combination with psycholeptics is classified in M09AA72, since these
combinations are used for treatment of nocturnal leg cramps.
Combinations used for cold conditions, containing quinine as an
antipyretic, are classified in R05X.
All enzyme preparations, which are used to treat inflammatory
conditions in the musculo-skeletal system, are classified in this group.
M09AX Other drugs for disorders of the musculo-skeletal system
Hyaluronic acid injection for intraarticular administration
(e.g. 2.5 mg/ampoule) used in the treatment of arthritis is classified in
this group. Hyaluronic acid injection used during surgical procedures on
the eye (e.g. 4-20 mg/ampoule) is classified in S01K.
The DDD for hyaluronic acid is based on intraarticular treatment of
arthritis. The DDD is assigned according to daily dose even if the
product is given as weekly injections.